Keith Betts
 
                    Education
Ph.D., biostatistics, Harvard University; M.A., biostatistics, University of California, Berkeley; B.S., applied mathematics, University of California, Los Angeles
Summary of Experience
Dr. Betts specializes in the application of advanced biostatistics techniques in the field of health economics and outcomes research (HEOR). He has broad experience developing research strategies in a range of disease areas, including endocrinology, immunology, hematology, neurology, oncology, psychiatry, virology, and women’s health. Dr. Betts has developed and applied new research methods in the fields of individualized medicine methodology, meta-analyses/indirect comparisons, causal inference, Bayesian statistics, missing data problems, and risk prediction. His expertise includes the design and analysis of clinical trials, health economics modeling, indirect comparisons/network meta-analysis, causal inference, psychometrics, survey design, and retrospective database analyses (including administrative claims, electronic medical records, and registry data). Dr. Betts’s work includes developing risk-benefit analyses, cost-effectiveness models, and network meta-analyses for regulatory submission as well as treatment pattern and burden-of-illness research to support the launch of emerging products. His research has been published in peer-reviewed statistical, medical, and health economics journals and presented at clinical and economic research conferences.
- 
                                                        Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled TrialsAdvances in Therapy, 2024 
 2024Mysler E, Burmester GR, Saffore CD, Liu J, Wegrzyn L, Yang C, Betts KA, Wang Y, Irvine AD, Panaccione R 
- 
                                                        Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparisonJournal of Comparative Effectiveness Research, 2024 
 2024Mahon R, Tiwari S, Koch M, Ferraris M, Betts KA, Wang Y, Gao S, Proot P 
- 
                                                        Real-world safety of first-line immuno-oncology combination therapies for advanced non-small-cell lung cancerFuture Oncology, 2024 
 2024Betts KA, Gao S, Ray S, Schoenfeld AJ 
- 
                                                        Tolvaptan and Number Needed to Harm in Autosomal Dominant Polycystic Kidney DiseaseKidney Medicine, 2024 
 2024
- 
                                                        
- 
                                                        Long-Term Temporal Trends of Real-World Healthcare Costs Associated with Nivolumab Plus Ipilimumab and Pembrolizumab Plus Axitinib as First-Line Treatment for Advanced or Metastatic Renal Cell CarcinomaOncology and Therapy, 2024 
 2024Du EX, Betts KA, Wang T, Kitchen SA, He X, Yin X, Guttenplan SB, Beauchamp K, Delgado A, Rosenblatt L 
- 
                                                        A Matching-Adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell CarcinomaEuropean Urology Oncology, 2023 
 2023McGregor B, Geynisman DM, Burotto M, Suárez C, Bourlon MT, Barata PC, Gulati S, Huo S, Ejzykowicz F, Blum SI, Tejo VD, Hamilton M, May JR, Du EX, Wu A, Kral P, Ivanescu C, Chin A, Betts KA, Lee CH, Choueiri TK, Cella D, Porta C 
- 
                                                        Impact on Hospitalizations of Long-Term Versus Short-Term Therapy with Sodium Zirconium Cyclosilicate During Routine Outpatient Care of Patients with Hyperkalemia: The Recognize I StudyExpert Review of Pharmacoeconomics and Outcomes Research, 2023 
 2023Pollack CV, Agiro A, Mu F, Cook EE, Wirtz EL, Young JA, Betts KA, Brahmbhatt YG 
- 
                                                        Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 studyJournal of Medical Economics, 2023 
 2023Chung Y, Maselli DJ, Mu F, Cook EE, Yang D, Young JA, Betts KA, Genofre E, Carstens D 
- 
                                                        Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-AnalysisValue in Health, 2023 
 2023Li X, Suh HS, Lachaine J, Schuh AC, Pratz K, Betts KA, Song J, Dua A, Bui CN 
- 
                                                        
- 
                                                        Real-world effectiveness of benralizumab: results from the ZEPHYR 1 StudyAnnals of Allergy, Asthma & Immunology, 2022 
 2022Chung Y, Katial R, Mu F, Cook E, Young J, Yang D, Betts K, Carstens D 
- 
                                                        Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survivalCancer Immunology, Immunotherapy, 2022 
 2022Weber JS, Poretta T, Stwalley BD, Sakkal LA, Du EX, Wang T, Chen Y, Wang Y, Betts KA, Shoushtari AN 
- 
                                                        Assessment of the relative effectiveness of erenumab compared with onabotulinumtoxinA for the prevention of chronic migraineCurrent Medical Research and Opinion, 2022 
 2022Mahon R, Vo P, Pannagl K, Tiwari S, Heemstra H, Ferraris M, Zhao J, Betts KA, Proot P 
- 
                                                        The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United StatesAdvances in Therapy, 2022 
 2022Woolley M, Cook EE, Mu F, Betts KA, Billmyer E, Yim E, Chen J, Wu EQ 
- 
                                                        Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapyJournal of Managed Care & Specialty Pharmacy, 2022 
 2022Choi M, Song J, Bui CN, Ma E, Chai X, Yin L, Betts KA, Kapustyan T, Montez M, LeBlanc TM 
- 
                                                        Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell CarcinomaClinical Drug Investigation, 2022 
 2022Geynisman DM, Burotto M, Porta C, Suarez C, Bourlon MT, Huo S, Del Tejo V, Du EX, Yang X, Betts KA, Choueiri TK, McGregor B 
- 
                                                        Value of Remission in Patients with Rheumatoid Arthritis: A Targeted ReviewAdvances in Therapy, 2022 
 2022
- 
                                                        Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinomaFuture Oncology, 2022 
 2022Geynisman DM, Du EX, Yang X, Sendhil SR, Tejo VD, Betts KA, Huo S 
- 
                                                        Benefit-Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid ArthritisRheumatology and Therapy, 2022 
 2022Conaghan P, Cohen S, Burmester G, Mysler E, Nash P, Tanaka Y, Rigby W, Patel J, Shaw T, Betts KA, Patel P, Liu J, Sun R, Fleischmann R 
- 
                                                        Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-AnalysisDermatology and Therapy, 2022 
 2022Armstrong AW, Soliman AM, Betts KA, Wang Y, Gao Y, Stakias V, Puig L 
- 
                                                        Real-World Management of Hyperkalemia in the Emergency Department: An Electronic Medical Record AnalysisAdvances in Therapy, 2022 
 2022Davis J, Israni R, Betts KA, Mu F, Cook EE, Anzalone D, Szerlip H, Yin L, Uwaifo GI, Wu EQ 
- 
                                                        CKD Progression and Economic Burden in Individuals with CKD Associated with Type 2 DiabetesKidney Medicine, 2022 
 2022Mullins CD, Pantalone KM, Betts KA, Song J, Wu A, Chen Y, Kong SX, Singh R 
- 
                                                        Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinomaJournal of Comparative Effectiveness Research, 2021 
 2021Parikh ND, Marshall A, Betts KA, Song J, Zhao J, Yuan M, Wu A, Huff KD, Kim R 
- 
                                                        A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid ArthritisRheumatology and Therapy, 2021 
 2021
- 
                                                        Inpatient Management and Post-Discharge Outcomes of HyperkalemiaHospital Practice, 2021 
 2021Davis J, Israni R, Mu F, Cook E, Szerlip H, Uwaifo G, Fonseca V, Betts K 
- 
                                                        Real-World Treatment Profiles, Clinical Outcomes, and Healthcare Resource Utilization of Patients with Migraine Prescribed Erenumab: A Multicenter Chart-Review Study of US Headache CentersNeurology and Therapy, 2021 
 2021Faust E, Pivneva I, Yang K, Betts KA, Ahmed Z, Joshi S, Hogan R, Blumenfeld A, Schim J, Feoktistov A, Carnes K, Bensink M, Wu EQ, Chou DE, Chandler D 
- 
                                                        Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysisDermatology and Therapy, 2021 
 2021Armstrong AW, Soliman AM, Betts KA, Wang Y, Gao Y, Puig L, Augustin M 
- 
                                                        Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial dataJournal of the American Academy of Dermatology, 2021 
 2021Shear NH, Betts KA, Soliman AM, Joshi A, Wang Y, Zhao J, Gisondi P, Sinvhal R, Armstrong AW 
- 
                                                        Determinants of Hyperkalemia Progression Among Patients with Mild HyperkalemiaAdvances in Therapy, 2021 
 2021Israni R, Betts KA, Mu F, Davis J, Wang J, Anzalone D, Uwaifo GI, Szerlip H, Fonseca V, Wu E 
- 
                                                        Prevalence of Metabolic Acidosis Among Patients with Chronic Kidney Disease and HyperkalemiaAdvances in Therapy, 2021 
 2021Cook EE, Davis J, Israni R, Mu F, Betts KA, Anzalone D, Yin L, Szerlip H, Uwaifo GI, Fonseca V, Wu EQ 
- 
                                                        Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia AJournal of Managed Care & Specialty Pharmacy, 2020 
 2020Zhou ZY, Raimundo K, Patel A, Han S, Ji Y, Fang H, Zhong J, Betts K, Mahajerin A 
- 
                                                        Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-AnalysisAdvances in Therapy 
 2020Pope J, Sawant R, Tundia N, Du EX, Qi CZ, Song Y, Tang P, Betts KA 
- 
                                                        
- 
                                                        Postdischarge Health Care Costs and Readmission in Patients With Hyperkalemia-Related HospitalizationsKidney International Reports, 2020 
 2020
- 
                                                        Number needed to treat and cost per remitter for biologic treatments of Crohn's disease in JapanJournal of Medical Economics, 2020 
 2020Ueno F, Doi M, Kawai Y, Ukawa N, Cammarota J, Betts KA 
- 
                                                        Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysisJAMA Dermatology, 2020 
 2020Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, Betts KA, Augustin M 
- 
                                                        Economic burden associated with tuberous sclerosis complex in patients with epilepsyEpilepsy & Behavior, 2020 
 2020Betts KA, Stockl KM, Yin L, Hollenack K, Wang MJ, Yang X 
- 
                                                        US cost–effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphomaJournal of Comparative Effectiveness Research, 2020 
 2020Betts KA, Thuresson PO, Felizzi F, Du EX, Dieye I, Li J, Schulz M, Masaquel AS 
- 
                                                        Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic ArthritisRheumatology and Therapy, 2019 
 2019
- 
                                                        Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial DataAdvances in Therapy, 2019 
 2019Freeman M, Betts KA, Jiang S, Du EX, Gupte-Singh K, Lu Y, Rao S, Shoushtari AN 
- 
                                                        The prevalence of hyperkalemia in the United StatesCurrent Medical Research and Opinion. 2018 Jun;34(6):971-978 
 2018
- 
                                                        Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized TrialsValue in Health. Jan 2018;21(1):1-8 
 2018Papp KA, Yang M, Sundaram M, Jarvis J, Betts KA, Bao Y, Signorovitch JE 
- 
                                                        Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysisCurrent Medical Research and Opinion. Apr 23 2018:1-9 
 2018Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Ganguli AX, Wu EQ 
- 
                                                        
- 
                                                        Number needed to treat and costs per responder among biologic treatments for moderate to severe psoriasisCurrent Medical Research and Opinion. 2018 Jul;34(7):1325-1333 
 2018Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Wu EQ 
- 
                                                        Concomitant Use of Psychotropic Medication With Stimulants for the Treatment of ADHD in Children and Adolescents: A Retrospective Insurance Claims Study in the United StatesJournal of Attention Disorders, July 1, 2018 
 2018Zhou Z, Betts KA, Bocharova I, Kinrich D, Spalding WM 
- 
                                                        Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 TrialCancer. 2018 Oct 15;124(20):4032-4043 
 2018Dimopoulos MA, Lonial S, Betts KA, Chen C, Zichlin ML, Brun A, Signorovitch JE, Makenbaeva D, Mekan S, Sy O, Weisel K, Richardson PG 
- 
                                                        Real-World Outcomes of Acute Ischemic Stroke Treatment with Intravenous Recombinant Tissue Plasminogen ActivatorJournal of Stroke and Cerebrovascular Diseases. Sep 2017;26(9):1996-2003 
 2017Betts KA, Hurley D, Song J, Sajeev G, Guo J, Du EX, Paschoalin M, Wu EQ 
- 
                                                        Comparative efficacy of long-acting beta2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysisInternational Journal of Chronic Obstructive Pulmonary Disease. 2017;12:367-381 
 2017Donohue JF, Betts KA, Du EX, Altman P, Goyal P, Keininger DL, Gruenberger JB, Signorovitch JE 
- 
                                                        Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trialsJournal of the American Academy of Dermatology. Dec 2017;77(6):1030-1037 
 2017Gordon KB, Betts KA, Sundaram M, Signorovitch JE, Li J, Xie M, Wu EQ, Okun MM 
- 
                                                        Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspectiveRheumatology International. Jun 16 2017:1-12 
 2017
- 
                                                        Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in JapanJournal of Dermatological Treatment. Feb 2018;29(1):24-31 
 2017
- 
                                                        Real-world costs of ischemic stroke by discharge statusCurrent Medical Research and Opinion. Feb 2017;33(2):371-378 
 2017Mu F, Hurley D, Betts KA, Messali AJ, Paschoalin M, Kelley C, Wu EQ 
- 
                                                        Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect ComparisonRheumatology Therapeutics. Jul 31 2017 
 2017
- 
                                                        Systematic Literature Review and Meta-analysis of Tumor Necrosis Factor-Alpha Experienced Rheumatoid ArthritisClinical Therapeutics. Aug 2017;39(8):1680-1694 e1682 
 2017Wells AF, Curtis JR, Betts KA, Douglas K, Du EX, Ganguli A 
- 
                                                        Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis after Etanercept Discontinuation in the United Kingdom, France, and GermanyClinical Therapeutics. Aug 2017;39(8):1618-1627 
 2017Li N, Betts KA, Messali AJ, Skup M, Garg V 
- 
                                                        Effect of Adalimumab on Visual Functioning in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 TrialsJAMA Ophthalmol. Jun 01 2017;135(6):511-518 
 2017Sheppard J1, Joshi A, Betts KA, Hudgens S, Tari S, Chen N, Skup M, Dick AD 
- 
                                                        Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis: Post Hoc Analyses from the VISUAL-1 and VISUAL-2 TrialsOphthalmology. Dec 2017;124(12):1799-1807 
 2017Suhler EB, Thorne JE, Mittal M, Betts KA, Tari S, Camez A, Bao Y, Joshi A 
- 
                                                        Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid ArthritisClinical Therapeutics, 2016 05; 38(5): 1205-1216. e-pub ahead of print 2016/04/06 
 2016
- 
                                                        Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor-alpha and Interleukin Inhibitors in the Treatment of Active Ankylosing SpondylitisRheumatology and Therapy, 2016 07: 1-14 
 2016Betts KA, Griffith J, Song Y, Mittal M, Joshi A, Wu EQ, Ganguli A. 
- 
                                                        ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvem(1)Rheumatology (Oxford). 2016 Jan;55(1):80-8. doi: 10.1093/rheumatology/kev267. Epub 2015 Aug 27 
 2016Van der Heijde D, Joshi A, Pangan AL, Chen N, Betts KA, Mittal M, Bao Y. 
- 
                                                        Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid ArthritisAdvances in Therapy, 2016 05; 33(5): 807-823. e-pub ahead of print 2016/04/17 
 2016
- 
                                                        Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infectionJ Comp Eff Res. 2015 Nov;4(6):593-605. doi: 10.2217/cer.15.33. Epub 2015 Jul 10. 
 2015Signorovitch JE, Betts KA, Yan Y, Sorg R, Li J, Behl AS, Kalsekar A. 
- 
                                                        Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm responseBr J Dermatol. 2015 Feb;172(2):504-12. doi: 10.1111/bjd.13437. Epub 2015 Jan 21. 
 2015Signorovitch JE, Betts KA, Yan YS, LeReun C, Sundaram M, Wu EQ, Mulani P. 
- 
                                                        Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneityJ Med Econ. 2012; 15(6):1078-87 
 2012Erder MH, Signorovitch JE, Setyawan J, Yang H, Parikh K, Betts KA, Xie J, Hodgkins P, Wu EQ 
- 
                                                        Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trialsCurr Med Res Opin. 2011 Jun;27(6):1263-71. Epub 2011 Apr 28 
 2011Signorovitch J, Wu EQ, Betts K, Parikh K, Kantor E, Guo A, Bollu V, Williams D, Wei L, DeAngelo D 
- 
                                                    June 20, 2024
- 
                                                    April 11, 2024
- 
                                                    February 1, 2024
- 
                                                    October 23, 2023
- 
                                                    April 5, 2022
- 
                                                    March 29, 2022
- 
                                                    July 20, 2021
- 
                                                    June 4, 2021
